Articles from: VJOncology
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve...
-
Did you miss ASCO #GI23? You can catch up on key updates and expert interviews in #GastrointestinalCancer on https://t.co/ys1d8pDAKO 🖥️ @VJOncology @asco #LiverCancer #ColorectalCancer #Pancsm #GIsm #CRCsm #HCCsm https://t.co/ys1d8pDAKO - view on twitter
Sibylle Loibl, MD, PhD, German Breast Group, Neu-Isenburg, Germany, shares her highlights from the San Antonio Breast Cancer Symposium...
-
🎥 @LoiblSibylle of @GBG_Forschung discusses key takeaways from SABCS 2022 Watch: 👉https://t.co/EjhIh2eD9u👈 @SABCSSanAntonio #SABCS22 #BCSM #BreastCancer - view on twitter
Mashup Score:1
VJOncologyWhat role will TILs play in treating patients with melanoma? - 2 days
Mashup Score:1
Maartje Rohaan, MD, Netherlands Cancer Institute, Amsterdam, The Netherlands, comments on the clinical implications of the recent findings of...
-
🎥 Maartje Rohaan of @NKI_nl talks on what role TILs will play in treating patients with melanoma Watch: 👉https://t.co/iFl0yhyhKC👈 @myESMO #ImmunoOnc - view on twitter
Virginia Kaklamani, MD, UT Southwestern Medical Center, Dallas, TX, talks on the predictive value of treatment response and residual...
-
🎥 @VKaklamani of @UTSWNews discusses the predictive value of treatment response after neoadjuvant therapy Watch: 👉https://t.co/exYtb9xT2S👈 @SABCSSanAntonio #SABCS22 #BCSM #BreastCancer - view on twitter
Mashup Score:1
VJOncologyOmitting total lymph node dissection and adjuvant therapy in melanoma - 3 days
Mashup Score:1
Following the results from the Phase II OpACIN-neo trial (NCT02977052) assessing ipilimumab and nivolumab in melanoma, pathologic response rate...
-
🎥 Irene Reijers of @NKI_nl discusses omitting total lymph node dissection and adjuvant therapy in melanoma Watch: 👉https://t.co/ZXr32CHsNA👈 @myESMO #ImmunoOnc #melanoma #melsm #skcsm - view on twitter
Mashup Score:2
VJOncologyTargeting local recurrence in pancreatic adenocarcinoma with proton therapy - 3 days
Mashup Score:2
Pancreatic adenocarcinoma is associated with a poor prognosis and a 5-year survival rate of 10%. Benjamin Adam Weinberg, MD,...
-
RT @benweinbergmd: Published by @VJOncology https://t.co/lXfsPMspxU - view on twitter
Mashup Score:1
VJOncologyTargeting local recurrence in pancreatic adenocarcinoma with proton therapy - 3 days
Mashup Score:1
Pancreatic adenocarcinoma is associated with a poor prognosis and a 5-year survival rate of 10%. Benjamin Adam Weinberg, MD,...
-
Published by @VJOncology https://t.co/lXfsPMspxU - view on twitter
Benjamin Adam Weinberg, MD, Georgetown University, Washington, DC, describes the trial design and rationale of the Phase I PROTON-PANC...
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve...
-
🎥Watch video interviews with top #CervicalCancer experts this Cervical Cancer Awareness Month! ⏩Head over to https://t.co/ys1d8pDAKO to catch up with the latest cervical cancer research! 👉https://t.co/ys1d8pDAKO 👈 - view on twitter
Rupert Bartsch, MD, Comprehensive Cancer Center Vienna, Vienna, provides an overview of the prospective, observational Phase IV ELEANOR (NCT04388384)...
🎥 Rupert Bartsch of @CCC_Vienna talks on ELEANOR: real-world study of extended adjuvant neratinib in HER2+/HR+ early breast cancer Watch: 👉https://t.co/31OKf0bkH0👈 @SABCSSanAntonio #SABCS22 #BCSM #BreastCancer - view on twitter